reduced the mortality in those with any feature of HIVAN by 57% [adjusted hazard ratio (AHR) 0.43, 95% confidence interval (CI) 0.22-0.85]. Of those patients with HIVAN who died, 79% died of renal failure as registered on their death certificate. Proteinuria and microcysts were shown to be poor prognostic indicators (AHR 1.36: 1.09-1.70 and 2.04: 1. 24-3.37 ). In patients with HIVAN alone followed for up to 2 years on cART, estimated glomerular filtration rate remained stable and there was a trend towards decreased proteinuria. cART improved survival in patients with isolated immune complex disease. Conclusions. As mortality is improved in patients with any feature of HIVAN or isolated immune complex
Introduction
Due to lack of documentation, the true prevalence of kidney disease in South Africa (SA) as well as information regarding renal biopsy histology in HIV-positive patients has been difficult to obtain. This is partly due to the very poor prognosis of HIV-related renal diseases without combined antiretroviral therapy (cART) in the era when the SA government denied access to cART. It is also due to assumptions that kidney pathology must always be HIV-associated nephropathy (HIVAN) in the setting of HIV.
In 1984, Pardo et al.
[1] described what is now widely recognized as the 'collapsing glomerulopathy' of HIVAN. This initial description has been substantiated by the works of Rao [2] and D'Agati [3] . Since the initial descriptions of HIVAN, the renal histological findings and associated immune complex diseases have been inconsistently described. For example, Szczech et al. [4] classified biopsies with features of HIVAN and immune complex disease jointly to reflect HIVAN. Gerntholtz et al. [5] grouped membranous nephropathy on its own, only later to add the caveat that 'in addition to pure membranoustype changes, some biopsies had features of classic HIVAN'. A number of immune complex diseases have been described in the setting of HIV, including, IgA nephropathy, a lupus-like glomerulonephritis (GN), membranous, post-infectious GN (PIGN), mesangiocapillary GN (MCGN) [6] and the 'ball-in-cup' phenomenon [5, 7] .
Clearly defining HIVAN, HIVAN plus immune complex diseases, immune complex diseases without HIVAN and diseases unrelated to HIV would enable standardization of outcomes of treatment regimens. It would also assist in prognosticating outcomes based on histology. In the future, treatment options may be more specific [8] .
We analysed HIV-positive kidney biopsies carried out at the Groote Schuur Hospital in an attempt to describe the histological spectrum, develop clinical correlations and prognostic indicators and determine outcomes based on histological findings.
We defined HIVAN as a constellation of glomerular, interstitial and tubular abnormalities. It was an additional requirement that there be epithelial cell hyperplasia/hypertrophy if only tubular or interstitial disease was present. Predominantly plasma cell infiltration characterized HIV interstitial disease. Microcysts also confirmed the diagnosis of HIVAN. For a broad overview, see Table 2 .
Materials and methods
The study was approved be the Research Ethics Committee of University of Cape Town. All renal biopsies from HIV-positive patients were retrospectively analysed from 2005 to September 2008 (n = 116) and prospectively thereafter until December 2010 (n = 105). Patient demographics, renal function, kidney size on ultrasound, protein/creatinine ratio (uPCR grams per millimole), CD4 count, viral load and serological markers were recorded (anti-nuclear antibody, anti-double-stranded DNA, VDRL, hepatitis B and C, anti-streptolysin titre, anti-DNase B titre and complement). All variables were obtained within 2 weeks of the renal biopsy. Drug history including date of commencing cART was obtained. The estimated glomerular filtration rate (eGFR) was calculated according to the Modification of Diet in Renal Disease equation [9] . Clinical features such as oedema, systolic and diastolic blood pressures (SBP and DBP) were noted. Where possible, patients from the retrospective cohort were recruited to the follow-up prospective clinic (n = 13). Mortality data was obtained from death certificates, patient folders, records from HIV clinics and family members.
Renal biopsies were processed for light microscopy with haematoxylin and eosin, methenamine silver and periodic acid-Schiff stains. Standard techniques were performed to demonstrate IgA, IgM, IgG and C3 for immunohistochemistry (IH) and electron microscopy (EM). A single histopathologist reviewed all biopsies. The histopathologist was aware of the HIV status of the patient when the biopsies were reviewed.
Glomeruli were examined for the histological subtypes of focal segmental glomerulosclerosis (FSGS) [10, 11] and/or immune complex diseases. Parietal epithelial cells (PECs) and podocytes were examined for the presence of hypertrophy, hyperplasia and mitotic figures as were tubular epithelial cells. Pseudocrescents were defined as hypertrophied and hyperplastic epithelial cells presumed to be podocytes. Phenotypic confirmation by special stains was not performed. Crescents were defined as proliferating epithelial cells with or without an admixture of fibroblasts. Non-HIV-associated immune complex diseases were diagnosed in the absence of epithelial cell involvement, plasma cell infiltration or microcysts. We defined the ball-in-cup phenomenon in accordance with the initial description i.e. large subepithelial deposits associated with a basement membrane reaction resulting in a 'ball-incup' architectural pattern [5, 7] .
Microcysts are the clincher of interstitial HIVAN and were defined as dilated tubules lined by flat epithelium and filled with proteinaceous material. However, any epithelial cell hypertrophy or hyperplasia in the setting of a plasma cell infiltrate supported the diagnosis of interstitial HIVAN. The proportion of lymphocytes, plasma cells and fibrosis was graded according to Table 1. In summary, HIV-associated kidney diseases were defined according to the histological features outlined in Table 2 .
Statistical methods
Patients' demographic and clinical characteristics were described for each histological group as proportions for categorical variables and as medians or means for continuous variables based on tests for normality, with interquartile ranges or 95% confidence intervals. These characteristics were compared between groups based on chi-squared, rank-sum or likelihood ratio tests, respectively.
Time to death was explored by histological group and cART status as Kaplan-Meier failure estimates and in univariable and multivariable Cox proportional hazard regression models. cART access was treated in these analyses as a time-varying exposure whereby patients who were not on cART at the time of biopsy but later started cART were censored from the 'not on cART' group at the time of starting cART and became at risk in the 'on cART' group. Histological associations with mortality (lymphocytic infiltrate, interstitial fibrosis and the presence of plasma cells and microcysts) were individually explored in multivariable Cox models that were further adjusted for cART and eGFR.
The evolution of eGFR and uPCR on cART was described for each histological group of patients with HIVAN as the change between the earliest available measurement around the time of starting cART (including up to 60 days prior to starting cART) and the most recent measurement before study closure, limited to patients who started cART during the study. This ensured that each patient contributed one data point to the analysis, presented as a series of scatter plots of this change against the time between measurements, overlaid by a linear prediction plot.
Results
Two hundred and twenty-one biopsies were performed, 15 were excluded due to inadequate sampling or end-stage kidney disease. If information regarding initiation of cART therapy was not obtainable and/or if the patients were lost to follow-up, these biopsies (14) were excluded from the outcome analysis making a total of 192 patients in the final analysis. One hundred and seventy-two patients (89.6%) were of Black African ethnic origin, 19 (9.9%) of mixed ancestry and in 1 case, ethnicity was not determined. There Table 2 . Defining kidney disease in HIV Renal histology in HIV with outcomeswere no Caucasians in this study. The majority of patients were on the cART regimen of stavudine, lamivudine and either nevirapine or efavirenz. There were no patients on addictive substances for example heroin. Optimal anti-proteinuric therapy with an angiotensin-converting enzyme inhibitor (ACEi) was inconsistently offered during the period when cART was not actively 'rolled out'.
The baseline characteristics of patients from the 192 biopsies are shown in Table 3 and the specific features of each group are described in Tables 4-6. A total of 34.8% of patients with any feature of HIVAN had an additional pathology.
HIVAN
We focussed on the glomerular diseases seen in those with pure HIVAN (i.e. n = 110) so that the influence of any immune complex disease was excluded from the analysis. Although the collapsing variant of FSGS (cFSGS) ( Figure 1A ) was most prevalent (47/110: 42.7%), other histological subtypes of FSGS were encountered including the perihilar variant ( Figure 1B ) [10] . In the case of other variants of FSGS attributed to HIV, additional histological features needed to be present i.e. PEC or podocyte hypertrophy or hyperplasia, microcysts or plasma cell interstitial infiltrate. We describe a new variant of FSGS which our pathologist has termed the 'fetal variant' [12, 13] as it resembles the histological conformation of a fetal glomerulus. This variant has a dense mesangial sclerotic core with no demonstrable peripheral loops or collapse. The inner region of Bowman's capsule is lined with a single layer of PECs. These are distant and separated from the hypertrophied and hyperplastic visceral epithelial cells on the surface of the inner core ( Figure 1C ). Diffuse mesangial sclerosis has been described by Barisoni et al. [11] ; however, the epithelial response appears to differ in this newly described variant. The podocytes do not remain in demonstrable clefts and become markedly hyperplastic and hypertrophied.
Of the 16 biopsies demonstrating mesangial deposits, only 5 glomeruli were positive for IgM, 4 for C3, 3 for IgA and one for IgG. There were also some cases demonstrating insignificant subendothelial and subepithelial deposits. There were 22 cases of HIVAN demonstrating positive IH without identifiable deposits on EM. Of these, a significant proportion had positive IH within epithelial cells. Tubuloreticular inclusions were not specifically looked for in this series.
HIVAN plus immune complex GN (HIVAN plus ICGN)
Nine biopsies had immune complex deposition with a 'ball-in-cup' appearance ( Figure 1D ). In all of these cases, there was at least one other defining feature of HIVAN. The ball-in-cup deposit was most commonly associated with C3 positivity.
In those patients with HIVAN plus other types of immune complex GN (ICGN), the immune complex was defined according to the classical diagnosis of the specific immune complex disease. This was also the case with immune complex disease alone without features of HIVAN. Except for the associations with hepatitis (B and C), as well as PIGN, all immune complex diseases without features of HIVAN were considered to be idiopathic.
There were seven cases of hepatitis B associated with the following GNs (three HIVAN, two HIVAN plus membranous GN, one HIVAN plus mesangialproliferative GN and one with PIGN). The urban SA hepatitis B/HIV coinfection rate has been estimated at 5% [14] . There were three cases of hepatitis C, one case had typical cFSGS, one had features of HIVAN plus membranous GN and the final case had membranous GN in isolation. SA has a low prevalence of HIV/hepatitis C co-infection reported as 1.9% [15] . There were nine cases of pseudocrescents and eight cases of crescentic disease in those with any feature of HIVAN.
Tubulointerstitial disease
Interstitial HIVAN occurred as a distinct variant in 19/110 cases. Plasma cell infiltration and microcysts are a common feature of this variant. Granulomas associated with clinical tuberculosis were seen in conjunction with features of HIVAN in nine biopsies.
Outcomes in HIV associated renal diseases
The 50% survival of those patients with HIVAN without cART is 4.47 months (Figure 2 ). cART improves renal outcome no matter when the patient is commenced on cART. Our median time to onset of cART initiation is 55 days following biopsy. We were able to obtain outcomes for 110 patients. Of the 47 renal deaths (on or off cART), 79% were due to renal failure, 1 patient received chronic dialysis and 1 patient was transplanted.
The outcomes of the glomerular variants of HIVAN and interstitial HIVAN were reviewed for a 12-month period (N = 114) (See Figure 3) . The 'fetal' variant was associated with the worst mortality. This mortality was compared with the collapsing variant which historically has been shown to have the worst response to cART [adjusted hazard ratio (AHR) = 2.75, 1.00-7.57].
If a biopsy featured HIVAN plus ICGN, then outcomes were improved on cART with a 50% survival of 5.09 months for those without cART (Figure 4) . Of the 15 renal deaths (on or off cART), 68% died of renal failure and 1 patient was transplanted.
In HIVAN, eGFR and proteinuria appear to improve over the follow-up period, although results were not significant ( Figure 5 ). In the group with ICGN alone, eGFR appeared to stabilize and proteinuria improve although numbers are small and results are not significant ( Figure 5) . Mortality was also shown to improve in the group with ICGN alone although numbers are small and there was only data to 12 months. Patients in the ICGN alone group did not receive other forms of therapy for their GN.
HIVAN and associations with mortality
Using a multivariable model (Table 7) , cART reduced the mortality in those with any feature of HIVAN by 57% (P = 0.016). Patients with better eGFR at presentation, as expected, had better outcomes (AHR 0.72, P = 0.001). Proteinuria and microcysts were shown to be poor prognostic indicators (AHR 1.36, P = 0.007; AHR 2.04, P = 0.005). CD4 count was not found to be a significant prognostic marker (AHR 1.04, P = 0.668). Interstitial fibrosis was negatively prognostic in the setting of HIVAN plus ICGN (AHR = 2.48, P = 0.006); however, this needs further evaluation with time. Serological markers were not found to be prognostic indicators. Viral loads were available for only a small proportion of patients at the time of biopsy and when available were not associated with histological diagnosis or eGFR. [2] and D'Agati [3] to establish a more thorough definition of HIVAN based on our local experience. The single morphological feature that confirmed HIV involvement in the kidneys was microcysts. cFSGS was the most common variant of FSGS; however, other histological subtypes were encountered [10] . This biopsy series describes a new glomerular variant which we have termed the 'fetal variant'. This variant may well be cFSGS in evolution.
PECs or epithelial cell progenitors may migrate around the dense mesangial sclerotic core and differentiate into visceral epithelial cells ( Figure 6 ). The origin of pseudocrescents is still to be conclusively determined [16] [17] [18] [19] .
The 'ball-in-cup' phenomenon may be attributed to HIV immune dysregulation. We suggest that the 'ball' in the initial description resembles humps seen in, for example, PIGN. The humps in PIGN are circulating complexes which are trapped in the subepithelial area. Similar trapping of immune complexes may occur as a results of HIV however the deposits are much larger.
MCGN was found to be commonly associated with HIVAN. This may be in keeping with data from our group demonstrating MCGN to be the most common form of GN in our area [20] . A lupus-like picture [21] was not seen in any biopsy in this series.
There were some significant differences in the baseline characteristics of the groups (see Table 3 ). CD4 count and eGFR were lowest in the group with diseases unrelated to HIV (median CD4 = 28, P = 0.029 and Cr = 409, P = 0.04). This probably represents significant acute kidney injury in the presence of those patients with sepsis, acute tubular necrosis and drug reactions. CD4 count is known to decrease in the setting of acute illness [23] .
In this series, the clinical correlations of nephrotic range proteinuria ≥0.35 g/mmol; SBP < 140 and DBP < 90 mmHg, kidney size on ultrasound ≥12 cm with no peripheral oedema were 91.3% specific for HIVAN but only 15.6% sensitive. As the sensitivity is poor and the frequency of finding an additional pathology is high (34.8% of those patients with any features of HIVAN had an additional pathology), this emphasizes the need to routinely perform renal biopsies wherever possible in these patients.
Most patients in the untreated group died of renal failure. This poor outcome reflects the lack of 'roll out' of cART during the SA government's 'denialist' period. During this period, patients were denied access to cART with a devastating impact. cART has only been actively administered in SA since 2004. Maintenance dialysis therapy was made available on a limited basis from 2008.
Any patient demonstrating the histological features of HIVAN (with or without immune complex disease) will have a mortality benefit on cART. In the group with HIVAN alone, there also appears to be an improvement in eGFR and reduction in proteinuria.
The 'fetal variant' had the worst prognosis on cART. This variant also had the heaviest proteinuria (median = 1.52 g/mmol) and most microcysts. Proteinuria and microcysts were also found to be negative prognostic indicators. The collapsing variant, previously shown to be a poor responder to cART [22] , did demonstrate a significant mortality benefit on cART. The mortality of the non-collapsing variant did not significantly improve on cART. This variant is perhaps less severe in nature and hence not so reliant on cART for improvement. Information regarding the use of the ACEi enalapril was very poorly documented particularly in the retrospective group of patients. Therefore, the influence of ACEi on proteinuria and outcome in this series is unknown and hence not reported by us.
It is difficult to explain why interstitial fibrosis was only found to be a significant prognostic indicator in the HIVAN plus ICGN group and not hold true for all groups (AHR = 2.48: P = 0.006). Perhaps it is related to the impact of dual pathologies in the HIVAN plus ICGN group.
There are studies that show that HIVAN can occur at any CD4 count [23] [24] [25] . As HIVAN can occur in patients with well-preserved CD4 counts, it is inevitable that we are missing patients who by other criteria are not eligible for cART. Kidney monitoring must commence at HIV diagnosis and be part of ongoing management.
Szczech et al. [4] stated that 'among patients with renal disease other than HIVAN, initiation of cART was not associated with a beneficial effect on renal function'.We demonstrated an improvement in proteinuria, stabilization in renal function (although results were not significant) and mortality benefit in the group with ICGN alone. We suggest that ICGN in the setting of HIV should be an indication for cART.
No randomized controlled trials have focussed on the treatment of HIV-related kidney disease despite its clinical importance. Our series only demonstrated an improvement in mortality of 57%, hence the need to develop more effective treatment strategies for all HIV-related kidney diseases. In vitro data has demonstrated up-regulation of many of the pro-inflammatory genes in renal tubular cells of individuals with HIVAN [26] . Corticosteroids may play a role in attenuating the interstitial inflammation so commonly seen in this condition. The experience in transplantation has shown that even with heavy immunosuppression, HIV-positive patients have an excellent outcome [27] .
Evaluating the reliability of the histopathological findings and definition for HIVAN by more than one histopathologist would be important to determine whether our system would be reproducible in practice. Further followup of our cohort would be useful in obtaining long-term outcome data. It was not possible to fully explore associations with viral load and pathology, as in SA viral load measurements are not standard of care for patients unless they are established on cART. The lack of documentation of the use of ACEi is a limitation of the study.
Conclusions
Early detection of HIV-associated renal diseases and initiation of cART in the setting of HIVAN is of paramount importance. cART dramatically improves outcome in any patient demonstrating any of the histological features of HIVAN (with or without immune complex disease) on renal biopsy. Renal biopsy is thus essential to correctly document renal disease in the HIV-positive population. We attempt to clearly define histological components of HIVAN. This will enable standardized histology to predict outcomes and response to treatment regimens. Further treatment strategies for HIV-related kidney diseases need to be urgently defined.
